Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells
Publication year
2012Source
Nanomedicine, 7, 10, (2012), pp. 1591-610ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Tumorimmunology
Journal title
Nanomedicine
Volume
vol. 7
Issue
iss. 10
Page start
p. 1591
Page end
p. 610
Subject
NCMLS 3: Tissue engineering and pathology; ONCOL 3: Translational research NCMLS 2: Immune RegulationAbstract
Current retroviral treatments have reduced AIDS to a chronic disease for most patients. However, given drug-related side effects, the emergence of drug-resistant strains and the persistence of viral replication, the development of alternative treatments is a pressing need. This review focuses on recent developments in HIV immunotherapy treatments, with particular emphasis on current vaccination strategies for optimizing the induction of an effective immune response by the recruitment of dendritic cells. In addition to cell-based therapies, targeted strategies aiming to deliver synthetic HIV peptides to dendritic cell-specific receptors in vivo will be discussed.
This item appears in the following Collection(s)
- Academic publications [238426]
- Faculty of Medical Sciences [90359]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.